Liraglutide imitates a hormone that helps control the appetite.
According to the expert, the Oliro drug should benefit from patients with obesity without resources for more expensive pens
A new version of the Liraglutide drug is coming to Brazil. It is Olol, launched by the pharmacist without. The differential is the reduced price of this medicine, since there has been a drop in patents, thus allowing the practice of more competitive values. Suitable for people with overweight associated with comorbidity or obesity, Olire is a slimming pen. It should therefore be applied subcutaneously, usually once a day. This medicine is also released for 12 -year -old young people to treat obesity and associated diseases such as dyslipidemia (high cholesterol).
Liraglutide is an analogue of GLP-1, a hormone that helps to control the appetite and regulation of the gcosio. In Brazil, it is approved by Anvisa both for the treatment of type 2 diabetes and for the management of obesity.
“With the fall of the patent and the most convenient amount, it will be possible to reach a part of the population that had no access to the cost before. This is very important, because, when they intervene in the hormonal issue, we can treat obesity more effectively,” says Dr. Renato de Araujo Pereira. It specializes in obesity treatments and member of the Brazilian society of bariatric and metabolic surgery (SBCBM).
Other pens: Ozepic and Wegovy
On the market, there are other options for penne for weight loss such as Ozepic and Wegovy, both based on trafficlutid. Both drugs offer a weekly dosage, a lower gastrointestinal effect rate and can involve weight loss from 10% to 15%. Already the Mounjaro, based on the Tipatide, combines the action on two hormones (GLP-1 and GIP), improving weight loss from 15% to 20%.
Studies indicate that the liraglutide (oil), while requesting a daily application and can have effects such as nausea and constipation, is an effective and now more competitive alternative, with a potential from 5% to 8% of the body weight. All are approved by Anvisa to treat obesity, with some particularities. Wegovy is exclusive for weight loss, while Ozepic and Mounjaro have main indications for diabetes and off-label use (outside the appointment described in the package of the package) for obesity under medical supervision.
75 million Brazilians
According to the Ministry of Health, about 75 million Brazilians overweight or obesity. Of this amount, 5.7 million are children between 5 and 9 years old. “Obesity is a growing concern and strengthens the urgency of public and educational policies that encourage food reworking and physical activity as a basis for the fight against the disease. There is consensus on the fact that healthy habits and balanced diet are fundamental for the success of the treatment”, explains Dr. Renato de Araujo Pereira.
He underlines that the treatment for obesity with pens for weight loss should have followed a doctor. “Without adequate guide, there is a risk of breaking weight. Therefore, the food re -enactment and the support of a multidisciplinary team are essential to ensure the maintenance of the results”, concludes the expert.
Edition: Fernanda Villas Bôas
Source: Terra
Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.
